FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1502627133> ?p ?o ?g. }

• W1502627133 endingPage "283" @default.
• W1502627133 startingPage "279" @default.
• W1502627133 abstract "HCV is the principal etiologic agent of post-transfusion (PTH) hepatitis. The incidence and course of HCV hepatitis in liver transplant recipients is not well established. To resolve this information deficit, all records of recipients of single liver transplant (OLTx) between March 1986 and March 1990 at the University of Pittsburgh in whom both the donor and recipients' pre-OLTx sera were available (n = 516) were reviewed. All sera were assayed for HCV antibody using a second generation ELISA method developed by Abbott Laboratories. On the basis of the anti-HCV status of the donor and recipient pre-OLTx sera, four groups could be classified: group I (donor-, recipient-) n = 375; group II (donor-, recipient+) n = 111; group III (donor+, recipient-) n = 25; and group IV (donor+, recipient+) n = 5. Post OLTx liver biopsies were obtained for a clinical indication in 473 of these 516 patients. The prevalence of anti-HCV among recipients pre-OLTx was 22.5% (116/516) which is three times greater than the 5.8% (30/516) prevalence in the donors. Histologic hepatitis not ascribable to any cause other than HCV occurred in 76/516 (15%) recipients: 42 in group I; 28 in group II; 6 in group III and none in group IV. The overall risk of HCV hepatitis at 6 months, 1 year and 2 years post-OLTx was 4.8% (25/516), 7.6% (39/516) and 10.1% (52/516), respectively. At each of these time intervals, no significant difference between groups for the prevalence of HCV hepatitis was evident. Twenty-one of the 76 recipients (28%) with histologic HCV hepatitis developed CAH, of which 9 were in group I, 11 in group II and 1 in group III. Two of 9 patients in group I developed cirrhosis. The 2-year graft survival and patient survival rates for each group ranged from 60 to 80% and 60 to 100%, respectively, with the poorest results in group III and the best results paradoxically in group IV. These data demonstrate that: (i) the overall rate of developing HCV hepatitis post OLTx is 15%, ranging from 0 to 25% in groups I to IV (ii) progression to CAH and cirrhosis can occur in HCV infected allografts at 2–5 years but is infrequent and (iii) presence of antibody to HCV pre-OLTx in either the donor or the recipient does not appear to place the recipient at an excessive risk for the development of HCV hepatitis. HCV is the principal etiologic agent of post-transfusion (PTH) hepatitis. The incidence and course of HCV hepatitis in liver transplant recipients is not well established. To resolve this information deficit, all records of recipients of single liver transplant (OLTx) between March 1986 and March 1990 at the University of Pittsburgh in whom both the donor and recipients' pre-OLTx sera were available (n = 516) were reviewed. All sera were assayed for HCV antibody using a second generation ELISA method developed by Abbott Laboratories. On the basis of the anti-HCV status of the donor and recipient pre-OLTx sera, four groups could be classified: group I (donor-, recipient-) n = 375; group II (donor-, recipient+) n = 111; group III (donor+, recipient-) n = 25; and group IV (donor+, recipient+) n = 5. Post OLTx liver biopsies were obtained for a clinical indication in 473 of these 516 patients. The prevalence of anti-HCV among recipients pre-OLTx was 22.5% (116/516) which is three times greater than the 5.8% (30/516) prevalence in the donors. Histologic hepatitis not ascribable to any cause other than HCV occurred in 76/516 (15%) recipients: 42 in group I; 28 in group II; 6 in group III and none in group IV. The overall risk of HCV hepatitis at 6 months, 1 year and 2 years post-OLTx was 4.8% (25/516), 7.6% (39/516) and 10.1% (52/516), respectively. At each of these time intervals, no significant difference between groups for the prevalence of HCV hepatitis was evident. Twenty-one of the 76 recipients (28%) with histologic HCV hepatitis developed CAH, of which 9 were in group I, 11 in group II and 1 in group III. Two of 9 patients in group I developed cirrhosis. The 2-year graft survival and patient survival rates for each group ranged from 60 to 80% and 60 to 100%, respectively, with the poorest results in group III and the best results paradoxically in group IV. These data demonstrate that: (i) the overall rate of developing HCV hepatitis post OLTx is 15%, ranging from 0 to 25% in groups I to IV (ii) progression to CAH and cirrhosis can occur in HCV infected allografts at 2–5 years but is infrequent and (iii) presence of antibody to HCV pre-OLTx in either the donor or the recipient does not appear to place the recipient at an excessive risk for the development of HCV hepatitis." @default.
• W1502627133 created "2016-06-24" @default.
• W1502627133 creator A5000933990 @default.
• W1502627133 creator A5022963653 @default.
• W1502627133 creator A5032714638 @default.
• W1502627133 creator A5041228176 @default.
• W1502627133 creator A5055162354 @default.
• W1502627133 creator A5073823141 @default.
• W1502627133 date "1993-01-01" @default.
• W1502627133 modified "2023-09-27" @default.
• W1502627133 title "Frequency and severity of HCV infection following orthotopic liver transplantation" @default.
• W1502627133 cites W1483772543 @default.
• W1502627133 cites W1972720578 @default.
• W1502627133 cites W1977733324 @default.
• W1502627133 cites W1983944114 @default.
• W1502627133 cites W2005820299 @default.
• W1502627133 cites W2006309458 @default.
• W1502627133 cites W2014435033 @default.
• W1502627133 cites W2016382125 @default.
• W1502627133 cites W2023157738 @default.
• W1502627133 cites W2038449539 @default.
• W1502627133 cites W2046150483 @default.
• W1502627133 cites W2066124462 @default.
• W1502627133 cites W2080487642 @default.
• W1502627133 cites W2086843270 @default.
• W1502627133 cites W2088867281 @default.
• W1502627133 cites W2120611109 @default.
• W1502627133 cites W2124628373 @default.
• W1502627133 cites W2132329817 @default.
• W1502627133 cites W2158619791 @default.
• W1502627133 cites W2170843437 @default.
• W1502627133 cites W2179658561 @default.
• W1502627133 cites W2339946342 @default.
• W1502627133 cites W2402699220 @default.
• W1502627133 doi "https://doi.org/10.1016/s0168-8278(05)80270-3" @default.
• W1502627133 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8228120" @default.
• W1502627133 hasPublicationYear "1993" @default.
• W1502627133 type Work @default.
• W1502627133 sameAs 1502627133 @default.
• W1502627133 citedByCount "23" @default.
• W1502627133 countsByYear W15026271332013 @default.
• W1502627133 countsByYear W15026271332016 @default.
• W1502627133 crossrefType "journal-article" @default.
• W1502627133 hasAuthorship W1502627133A5000933990 @default.
• W1502627133 hasAuthorship W1502627133A5022963653 @default.
• W1502627133 hasAuthorship W1502627133A5032714638 @default.
• W1502627133 hasAuthorship W1502627133A5041228176 @default.
• W1502627133 hasAuthorship W1502627133A5055162354 @default.
• W1502627133 hasAuthorship W1502627133A5073823141 @default.
• W1502627133 hasConcept C120665830 @default.
• W1502627133 hasConcept C121332964 @default.
• W1502627133 hasConcept C126322002 @default.
• W1502627133 hasConcept C2776029263 @default.
• W1502627133 hasConcept C2776455275 @default.
• W1502627133 hasConcept C2779609443 @default.
• W1502627133 hasConcept C2911091166 @default.
• W1502627133 hasConcept C61511704 @default.
• W1502627133 hasConcept C71924100 @default.
• W1502627133 hasConcept C90924648 @default.
• W1502627133 hasConceptScore W1502627133C120665830 @default.
• W1502627133 hasConceptScore W1502627133C121332964 @default.
• W1502627133 hasConceptScore W1502627133C126322002 @default.
• W1502627133 hasConceptScore W1502627133C2776029263 @default.
• W1502627133 hasConceptScore W1502627133C2776455275 @default.
• W1502627133 hasConceptScore W1502627133C2779609443 @default.
• W1502627133 hasConceptScore W1502627133C2911091166 @default.
• W1502627133 hasConceptScore W1502627133C61511704 @default.
• W1502627133 hasConceptScore W1502627133C71924100 @default.
• W1502627133 hasConceptScore W1502627133C90924648 @default.
• W1502627133 hasIssue "3" @default.
• W1502627133 hasLocation W15026271331 @default.
• W1502627133 hasLocation W15026271332 @default.
• W1502627133 hasOpenAccess W1502627133 @default.
• W1502627133 hasPrimaryLocation W15026271331 @default.
• W1502627133 hasRelatedWork W1963598722 @default.
• W1502627133 hasRelatedWork W2049581320 @default.
• W1502627133 hasRelatedWork W2054405008 @default.
• W1502627133 hasRelatedWork W2091491906 @default.
• W1502627133 hasRelatedWork W2126956071 @default.
• W1502627133 hasRelatedWork W2399503113 @default.
• W1502627133 hasRelatedWork W2414855532 @default.
• W1502627133 hasRelatedWork W2467770546 @default.
• W1502627133 hasRelatedWork W2791688786 @default.
• W1502627133 hasRelatedWork W3023445469 @default.
• W1502627133 hasVolume "18" @default.
• W1502627133 isParatext "false" @default.
• W1502627133 isRetracted "false" @default.
• W1502627133 magId "1502627133" @default.
• W1502627133 workType "article" @default.